Publications
  1. (89)Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment

    Pool, M., Kol, A., de Jong, S., de Vries, E. G. E., Lub-de Hooge, M. N. & Terwisscha van Scheltinga, A. G. T. 2017 In : mAbs. 9, p. 1370-1378 9 p.

    Research output: Contribution to journalArticle

  2. ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells

    Kol, A., Terwisscha van Scheltinga, A., Pool, M., Gerdes, C., de Vries, E. & de Jong, S. 11-Jul-2017 In : Oncotarget. 8, 28, p. 45432-45446 15 p.

    Research output: Contribution to journalArticle

  3. (89)Zr-Onartuzumab PET imaging of c-MET receptor dynamics

    Pool, M., van Scheltinga, A. G. T. T., Kol, A., Giesen, D., de Vries, E. G. E. & Lub-de Hooge, M. N. Aug-2017 In : European Journal of Nuclear Medicine and Molecular Imaging. 44, 8, p. 1328-1336 9 p.

    Research output: Contribution to journalArticle

  4. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab

    Pool, M., Kol, A., Lub-de Hooge, M. N., Gerdes, C. A., de Jong, S., Vries, de, E. G. E. & Terwisscha van Scheltinga, A. G. T. 18-Oct-2016 In : Oncotarget. 7, 42, p. 68111-68121 11 p.

    Research output: Contribution to journalArticle

View all (7) »

View graph of relations

ID: 378071